Since the deleterious effect of olanzapine on insulin secretion was reverted by the co-treatment with an ER stress inhibitor, individuals with schizophrenia receiving treatment with this SGA could follow a combinatorial therapy aimed to reduce ER stress-induced beta cell dysfunction. The gene discussed is INS; the disease is schizophrenia.